|75.24||-41.73||-35.68%||Vol 5.78M||1Y Perf -29.35%|
|Apr 19th, 2021 15:29 DELAYED|
|-21.95 -18.77%||- -|
|Target Price||153.80||Analyst Rating||Moderate Buy 1.67|
|Potential %||102.58||Finscreener Ranking||★★+ 49.29|
|Insiders Trans % 3/6/12 mo.||-100/-100/-92||Value Ranking||★★★ 50.84|
|Insiders Value % 3/6/12 mo.||-100/-100/-92||Growth Ranking||★★★★ 62.56|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-90||Income Ranking||— -|
|Market Cap||3.82B||Earnings Rating||Buy|
|Price Range Ratio 52W %||1.68||Earnings Date||4th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2021|
|Estimated EPS Next Report||0.69|
|EPS Growth Next 5 Years %||10.00|
|Avg. Weekly Volume||1.27M|
|Avg. Monthly Volume||636.13K|
|Avg. Quarterly Volume||497.22K|
Haemonetics Corporation (NYSE: HAE) stock closed at 116.97 per share at the end of the most recent trading day (a -1.34% change compared to the prior day closing price) with a volume of 156.94K shares and market capitalization of 3.82B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 3004 people. Haemonetics Corporation CEO is Christopher A. Simon.
The one-year performance of Haemonetics Corporation stock is -29.35%, while year-to-date (YTD) performance is -1.5%. HAE stock has a five-year performance of 242.02%. Its 52-week range is between 74.1 and 142.11, which gives HAE stock a 52-week price range ratio of 1.68%
Haemonetics Corporation currently has a PE ratio of 53.70, a price-to-book (PB) ratio of 8.04, a price-to-sale (PS) ratio of 9.18, a price to cashflow ratio of 37.90, a PEG ratio of 2.32, a ROA of 8.11%, a ROC of 12.26% and a ROE of 16.08%. The company’s profit margin is 14.02%, its EBITDA margin is 25.80%, and its revenue ttm is $645.43 Million , which makes it $12.70 revenue per share.
Of the last four earnings reports from Haemonetics Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.69 for the next earnings report. Haemonetics Corporation’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for Haemonetics Corporation is Moderate Buy (1.67), with a target price of $153.8, which is +102.58% compared to the current price. The earnings rating for Haemonetics Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Haemonetics Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Haemonetics Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 11.84, ATR14 : 4.21, CCI20 : 107.45, Chaikin Money Flow : -0.03, MACD : -2.96, Money Flow Index : 63.03, ROC : 4.09, RSI : 38.08, STOCH (14,3) : 71.86, STOCH RSI : 0.54, UO : 45.10, Williams %R : -28.14), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Haemonetics Corporation in the last 12-months were: Charles J. Dockendorff (Option Excercise at a value of $432 420), Charles J. Dockendorff (Sold 12 180 shares of value $1 638 575 ), Christopher A. Simon (Sold 56 029 shares of value $4 956 801 ), Christopher Simon (Sold 1 008 shares of value $101 244 ), Dan Goldstein (Option Excercise at a value of $189 426), Dan Goldstein (Sold 8 746 shares of value $925 972 ), Jacqueline Scanlan (Option Excercise at a value of $120 298), Jacqueline Scanlan (Sold 15 943 shares of value $1 441 829 ), Josep Llorens (Sold 208 shares of value $19 707 ), Michelle L. Basil (Sold 25 673 shares of value $2 321 495 ), Richard J. Meelia (Option Excercise at a value of $367 557), Richard J. Meelia (Sold 10 353 shares of value $1 393 927 ), Robert E. Abernathy (Buy at a value of $647 440), William P. Burke (Sold 24 552 shares of value $2 225 558 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.